Navigation Links
Genetic difference predicts antidepressant response
Date:1/23/2008

Researchers have identified subtle genetic variations that predict the efficacy of two widely used antidepressant drugs. They found that certain variants in the gene for a protective transporter protein that pumps drugs and other substances out of the brain compromise the effectiveness of the antidepressants citalopram (trade name Celexa) and venlafaxine (Effexor).

The researchers said their findings indicate that genetic testing could help predict the responses of patients to particular antidepressants. More broadly, they said, such tests could help predict the efficacy of any drugs used to treat neurological disease.

Manfred Uhr and colleagues published their findings in the January 24, 2008, issue of the journal Neuron, published by Cell Press.

Antidepressants are the first-line treatment for major depression, but their overall clinical efficacy is unsatisfactory, as remission occurs in only one-third of the patients after a trial with an adequately dosed single drug, and remission rates further decline following successive treatment failures, wrote the researchers. This situation is particularly alarming in view of the fact that major depression constitutes one of the greatest disease burdens worldwide and is anticipated to be the second leading global disease burden by the year 2020, trailing only cardiovascular disease.

One reason for such poor response rates, said the researchers, is that protective transporter proteins pump such substances as drugs and some hormones back into the bloodstream, preventing them from crossing the blood-brain barrier.

In their studies, the researchers explored the function of one such transporter protein, called P-gp, in preventing the entry of antidepressants into the brain. They first knocked out genes for the transporter protein in mice and administered the antidepressants to the animals. The researchers found that brain concentrations of citalopram and venlafaxine were regulated by P-gpthat the antidepressants were thus substrates of the transporter.

Studying 443 patients on the antidepressants, they next searched for variants in the human gene that correlated with reduced efficacy of the drugs. Their genetic analysis identified 11 such variants.

To our knowledge, our results provide for the first time evidence that genetic variants in the [gene for P-gp] account for differences in the clinical efficacy of antidepressants, most likely by influencing their access to the brain, they wrote.

The general conclusion to be drawn is that any drug administered to treat CNS diseases should be analyzed for its P-gp substrate status, which can be determined by using knockout mice. From a clinical point of view, the findings warrant that patients receiving a drug that is a P-gp substrate for the treatment of brain diseases are genotyped to exclude the possibility that a patient receives a drug that fails to enter the CNS to an extent required for efficacy.

The researchers also suggested that development of future antidepressants should take into account whether the candidate drugs are transported by P-gp. And, clinical trials of antidepressants should be designed to take into account the P-gp genetic status of patients in the trial.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Genetics May Determine Antidepressants Effectiveness
2. Genetics Influence Blood Pressure Medications
3. Lupus in women: New genetic risk factors identified
4. Scripps research scientists find new genetic mutation that halts the development of lupus
5. Genetic Mutations Boost Prostate Cancer Risk
6. People with anorexia less likely to be blamed when biology, genetics explained
7. Years-Long Search Unlocks Deadly Genetic Disease
8. Brain imaging and genetic studies link thinking patterns to addiction
9. Human genetic variation -- Sciences Breakthrough of the Year
10. Top10 research advances include studies on genetics and stem cell research, stents
11. Twins study shows genetic basis for face and place recognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Paul Vitenas, ... the nation’s top level plastic surgeons, invited to attend Allergan’s recent meeting with their ... most valued companies in the world, Allergan is bringing a newly defined structure to ...
(Date:7/24/2017)... ... 24, 2017 , ... The Magic Wand® Rechargeable, the top-of-the-line ... favorite sex toy. Created in collaboration with website Kinkly.com, the award was the ... The Magic Wand Rechargeable won in stiff competition from brands such as Lelo, ...
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... Summer ... rain storms wreak havoc across communities and often result in massive tree damage requiring ... actions homeowners can take now including tree trimming, tree cabling and hazardous tree removal. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Right now, ... , The agency is hammering out a game plan to implement changes and ... ever to affect FDA-regulated firms. The new law:, ,     Seeks ...
(Date:7/24/2017)... Long Island (PRWEB) , ... July 24, 2017 ... ... of a new office at 2307 Bellmore Avenue, Bellmore, New York, (516) 784-5858. ... dermatologist Jordan Fabrikant, M.D. and physician assistants Lori Friedman and Fruma Leah Wiederman. ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... LOS ANGELES , July 12, 2017 CarpalAID is ... without drugs, braces or surgery. Carpal tunnel syndrome affects ... tunnel syndrome at twice the rate of men. The common methods ... steroids, or mobilization with uncomfortable hand braces or gloves. ... CarpalAID is a ...
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/10/2017)... , July 10, 2017  BDI Group subsidiary ... patient support services organization serving specialty pharmacies, home ... launch of four significant, value-added member programs designed ... better manage reimbursement and improve access and affordability ... therapies. ...
Breaking Medicine Technology: